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ABSTRACT 
The interaction between some chemokines with tumoral and stromal cells can influence tumor progression. CXCL9, a 
monokine induced by interferon gamma (MIG), targets lymphocytes. The aim of our study was to identify and quantify 
CD4+ and CD8+ T cells in the stroma of human breast cancer and correlate them with the presence of MIG/CXCL9. In 
58 specimens of human breast carcinoma and 10 normal breast tissue from mammoplasty surgery, immunohistochemis- 
try and ELISA methods were performed. The number of CD4+ and CD8+ T cells in breast cancer tissue was signifi-
cantly increased compared with normal breast tissue with a clear predominance of CD8+ T cells. MIG/CXCL9 levels 
were significantly elevated respect normal breast tissue. This chemokine correlated with the number of CD8+ T cells 
only in non-metastatic tumors. These data suggest that MIG targets cytotoxic T cells. Their recruitment into breast car-
cinoma can play a critical role in malignant progression, inhibiting the production of metastasis. 
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1. Introduction 
Tumor infiltrating lymphocytes (TIL) are a common 
finding in almost tumors. In breast cancer, one of the 
tumors with major impact in women’s health, these im-
mune cells infiltrate the stroma indicating a cellular im-
mune response of uncertain result. It remains unclear 
weather immune response influences the tumor growth 
and so as the mechanisms involved in immune cells re-
cruitment. Nevertheless, kinetics experimental studies of 
tumor infiltrating lymphocytes in mice challenged in the 
mammary region with an aggresive tumor cell line dem-
onstrated that T cells are recruited in stroma of murine 
breast tumor after the first week of the challenge. Gradu-
ally CD4+ T cells subpopulation diminishes and an in-
crease of CD8+ T cells is observed. The presence of 
these lymphocytes was considered the expression of an 
antitumor immune response, capable of preventing pro-
gression and metastasis [1]. 
In cancer progression, tissue homeostasis is perturbed. 
Stroma resident cells and tumor cells locally secrete 
soluble factors such as proteases, growth factors, cyto-
kines and chemokines favouring the recruitment of cells 
such as T cells, mast cells, macrophages and dendritic 
cells [2]. Chemokines represent a family of small mo-
lecular weight chemotactic cytokines regulating leuko-
cyte trafficking and other biological functions such as 
angiogenesis/angiostasis [3,4].  
It is known that in breast cancer, tumor cells produce 
CCL5/RANTES and the level of expression correlates 
with the extent of macrophage infiltration and lymph 
node metastasis. In esophageal carcinoma, CCL2/MCP1 
expression is correlated with the level of macrophage 
infiltration, tumor angiogenesis and invasion [5]. These 
and others acumulating data show that chemokines can 
serve as tissue specific attractants molecules for recruit-
ment of immune cells in cancer tissue. 
Given that chemokines play an important roles in mul-
tiple steps of tumor progresssion and metastasis, a che- 
mokine candidate suggested as a potential recruitment 
factor includes interferon-induced MIG/CXCL9 member 
of the non-ERL-CXC chemokine family [6]. This che- 
mokine is secreted by stromal cells, macrophages, den-
dritic cells and B cells. MIG/CXCL9 interact with 
CXCR3 receptor. This receptor is highly expressed on T 
helper-1 (Th-1) cells, effector CD8+ T cells and innate- 
type cells such as natural killer (NK), macrophages and 
dendritic cells. All these cells are recruited to tumoral 
stroma and MIG/CXCL9 specifically can interact with T 
cells [7-9].  
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It is demonstrated that in human gastric and colorectal 
carcinoma signifinat levels of CXCL9 and CXCL10 are 
produced by stromal cells and are correlated with 
CXCR3-positive TIL [10]. These carcinomas are associ-
ated with a good prognosis [11]. 
Over the last years there are few works studying the 
presence of MIG/CXCL9 in human breast carcinomas in 
the bibliography [2,3,12]. On the other hand, in murine 
models the role of MIG/CXCL9 in growth suppression of 
breast tumors as well as metastasis establishment is 
widely proven [13,14]. 
The aim of our study was to identify and quantify the 
presence of CD4+ and CD8+ T cells in the stroma of 
human breast cancer and examine the correlation be-
tween these lymphocytes and MIG/CXCL9 with the ob-
jective of providing new insights on microenvironment 
contribution to tumor progression. 
2. Materials and Methods 
2.1. Patients 
Tumor tissues were surgically obtained from 58 female 
patients, ranging in age from 43 to 75 years, with pri-
mary infiltrating breast carcinoma. They were all treated 
by wide excision of the tumor or total mastectomy. 
Histopathological types and tumor stages were classified 
according the International System of Nothinghan. His-
tological diagnosis was performed using routine methods. 
It should be emphasized that none of patients received 
chemotherapy before the study and none of them pre-
sented evidence of local o systemic infection. As control 
10 samples of normal breast tissue from mammoplasties 
were used. After excision, each specimen was fixed in 
10% buffered formalin for paraffin embedding. Simulta-
neously each specimen was divided into two parts: half 
of the tissue was snaped and cryostat sections for immu-
nohistochemical staining with monoclonal antibodies 
(mAb) applicable only on frozen sections. The remaining 
half was stored in liquid nitrogen to be used for MIG 
chemokine determination by ELISA (Enzime Linked 
Immunosorbent Assay). The methods performed did not 
have influence on the diagnostic and therapeutic proce-
dures for patients and there was no conflict with the 
ethical requirements of the Bioethic Commitee of our 
hospital. 
2.2. Immunochemistry 
Frozen sections were employed to detect CD4+ and 
CD8+ T cells with mAb CD4+ (T cell helper/inducer 
BioGenex) and mAb CD8 (T cell supressor/cytotoxic 
BioGenex). After incubation with the primary antibody, 
the sections were washed in PBS and incubated with 
biotynilated link antibody. The estreptavidin-peroxidase 
complex (Vectastain ABC KIT, Peterborough, England) 
was used to immunohistochemical staining and carbazol 
chromogen was used for visualization. Finally, sections 
were counterstained with Mayer haematoxylin (BioPack, 
MR, Buenos Aires, Argentina) and mounted with glyc-
erol-vinyl aqueous solutions (Zymed Lab. Inc. San Fran-
cisco, USA). 
2.3. ELISA Analysis 
Tumor tissues and control tissues were mechanically 
homogenized with a micro blender immersed in an ice 
bath with a saline solution (PBS) balanced at 7.4 pH in a 
1:2 relation; tissue volume/PBS volume. Homogenates 
were centrifuged for 1 hour at 8.000 rpm at 4˚C. Super-
nants were used for determining the presence of MIG by 
ELISA. Anti-human MIG (mAb) and goat anti-human 
polyclonal biotinylated murine monoclonal antibodies 
were used following the manufacturers’ instructions. 
Briefly each ELISA plate was covered with anti-MIG 
(mAb) in a concentration of 2 µg/ml with PBS overnight 
at 37˚C. After washing with PBS, each well was filled 
with blocking solution (PBS with 1% albumin bovine 
and 5% sucrose) and was incubated for 3 hours at room 
temperature. After washing with PBS the wells were 
covered with 100 µl of supernatant of normal and tu-
moral tissues and the plate was incubated at 37˚C for 2 
hours. After washing three times with PBS 100 µl of 
polyclonal biotinylated anti-MIG were added to each 
well and incubated for 1 hour at 37˚C. The plates were 
washed 3 times with PBS and 100 µl of a 1:1000 dilution 
of conjugate of streptavidine and peroxidase were added 
to each well. After a 30-min incubation at 37˚C, the plate 
was washed three times with PBS, 100 µl of a 1:1 mix-
ture of H2O2 with tetramethylbenzidine were added and 
incubated at room temperature after 30 minutes. The re-
action was stopped with 50 µl of H2SO4, 2M. Absorb-
ance was measured using a microplate reader at 450 nm. 
Results are expressed as quotient stated as follows:  
Absorbance of tumor tissueQuotient
Mean absorbance of normal tissues 2 SD
   
Results greater or equal to 1.0 are considered to be 
positive for the presence of MIG. 
2.4. Computerized Image Analysis 
T cells were counted using a digital image analyzer (Im-
agePro v6.3 Media Cybernetics, USA). For this purpose 
immunohistochemically stained cells were recognized 
using the color cube option of the count/size function of 
the software. For that purpose cell-containing tissue im-
ages were captured using a digital camera (Olympus 
DP71, Olympus, Japan). Ten images (1360 × 1024 reso-
lution, spatial resolution up to 0.16 µm/pixel, RGB and 
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TIFF format) were captured from each sample. The total 
number of cells was registered in 10 images. Data ob-
tained were exported to a spreadsheet to perform a statis-
tical analysis.  
2.5. Statistical Analysis 
Data obtained were statistically analyzed by Student’s t 
test and Spearman’s correlation test. P < 0.05 values 
were considered significant. 
3. Results 
The stroma of all breast cancers showed a great number 
of CD4+ and CD8+ T cells (2544 ± 540 cel/mm2 and 
6872 ± 970 cel/mm2, respectively). Their number was 
significantly increased with respect to control normal 
breast tissue (CD4+ cells: 1130 ± 122 cel/mm2 and CD8+ 
cells: 457 ± 98 cel/mm2). Additionally, in breast tumors 
an inverted CD4+: CD8+ ratio (1:2) between these lym-
phocytes subsets was observed (normal breast 2:1 ratio). 
Figure 1 
In 84% of tumors the presence of MIG/CXCL9 was 
detected, expressed as it was indicated in materials and 
methods (quotient average = 2.12 ± 1.17). In the remain-
ing 16% the quotient was lower than 1 and considered 
negative. There was a low expresión of MIG/CXCL9 in 
normal breast tissues (Figure 2). 
In tumors with metastasis there was no correlation 
between the presence of CD4+ and CD8+ T cells and 
MIG/CXCL9 expression. In tumors without metastasis 
there was a significantly positive correlation between the 
number of CD8+ T cells and Mig/CXCL9 (p < 0.02) 
(Figure 3).  
4. Discussion 
In breast cancer, tumor growth is modulated by a com-
plex interaction between tumor cells and immune cells, 
cytokines and chemokines [15]. Despite the presence of 
T cells in tumor microenvironment, antitumor immune 
response is ineffective and the tumor growths and metas-
tasizes. The function of those lymphocytes seems to be 
suppressed. Multiple mechanisms of immune supression 
that act in the tumor microenvironment have been pro-
posed and several of these have been validated to be 
functionally important in preclinical studies [16]. For 
instance, preliminary data have suggested that melanoma 
metastasis that contain CD8+ T cells show greater pres-
ence of FoxP3+ regulatory T cells, as well a higher ex-
pression of PD-1 and IDO (Indoleamine-2,3-dioxige- 
nase), supporting the notion that the tumor microenvi-
ronment can be rich in suppressive mechanisms that 
could contribute to cell disfunction [17]. However, there 
are data showing that in some gastric tumors, the pres-
ence of great number of tumor-infiltrating lymphocytes is  
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Figure 1. Increased number of CD4+ and CD8+ T cells in 
the stroma of breast cancer as compared with normal 
breast tissue with an inverted ratio. 
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Figure 2. Presence of MIG/CXCL9 in breast cancer as com-
pared with normal breast tissue. 
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Figure 3. Positive correlatio etween MIG/CXCL9 and 
ssociated with better prognosis. The majority of these 
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stromal CD8+ T cells in breast carcinoma without lymph 
node metastasis. 
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lymphocytes were positive for CXCR3 receptor and its 
ligand MIG/CXCL9 was abundantly expressed by stro-
mal cells and a small number of cancer cells [18,19]. 
MIG/CXCL9 expression promotes an immune cell infíl-
trate which could have the capacity to control tumor 
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growth and metastasis [20]. For instance, in renal cell 
carcinoma the increase of MIG/CXCL9 expression is 
associated with a more favourable prognosis. Its role in T 
cell recruitment and its antitumorigenic activity was 
demonstrated [21]. Other studies have shown that when 
the MIG/CXCL9 level in the tumor microenvironment is 
high, the metastatic capacity of tumor cells is considera-
bly reduced [20]. 
Our results indicate that there are an increase of 
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